RNA干扰球形核酸治疗复发胶质母细胞瘤的首次人体0期临床研究
本研究在非人灵长类毒理与毒代动力学基础上,开展单臂、开放标签、首次人体0期试验(NCT03020017),评估全身给予携带Bcl2L12 siRNA的球形核酸(NU-0129)治疗复发胶质母细胞瘤的安全性、药代动力学、瘤内蓄积与基因抑制活性。结果显示无4级或5级治疗相关毒性,静脉给药后SNA可到达肿瘤,且胶质瘤细胞摄取与Bcl2L12蛋白表达降低相关。
要点
- NU-0129在复发GBM患者中未出现4级或5级治疗相关毒性。
- 静脉给予的SNA可到达患者肿瘤,并见于肿瘤相关内皮、巨噬细胞和肿瘤细胞。
- 胶质瘤细胞对NU-0129的摄取与肿瘤相关Bcl2L12蛋白表达降低相关。
核心结论
- SNA纳米偶联物可作为潜在的可穿透血脑屏障的精准医学方法,用于GBM的全身治疗。
研究设计与样本
- 在非人灵长类中开展毒理学与毒代动力学研究,并开展单臂、开放标签、首次人体0期试验(NCT03020017)。
- 复发GBM患者接受静脉给予siBcl2L12-SNA(NU-0129),剂量为未观察到不良事件水平的1/50,随后行肿瘤切除术。
主要发现
- 安全性评估显示无4级或5级治疗相关毒性。
- 电感耦合等离子体质谱、X射线荧光显微镜和银染色显示静脉给予的SNA到达患者肿瘤,金富集见于肿瘤相关内皮、巨噬细胞和肿瘤细胞。
- 比较匹配的原发肿瘤与NU-0129治疗的复发肿瘤,胶质瘤细胞对NU-0129的摄取与肿瘤相关Bcl2L12蛋白表达降低相关。
临床怎么用
- 该0期研究提示NU-0129在复发GBM患者中具备初步安全性和瘤内递送证据,支持后续临床开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma (GBM) is one of the most difficult cancers to effectively treat, in part because of the lack of precision therapies and limited therapeutic access to intracranial tumor sites due to the presence of the blood-brain and blood-tumor barriers. We have developed a precision medicine approach for GBM treatment that involves the use of brain-penetrant RNA interference-based spherical nucleic acids (SNAs), which consist of gold nanoparticle cores covalently conjugated with radially oriented and densely packed small interfering RNA (siRNA) oligonucleotides. On the basis of previous preclinical evaluation, we conducted toxicology and toxicokinetic studies in nonhuman primates and a single-arm, open-label phase 0 first-in-human trial (NCT03020017) to determine safety, pharmacokinetics, intratumoral accumulation and gene-suppressive activity of systemically administered SNAs carrying siRNA specific for the GBM oncogene Bcl2Like12 (Bcl2L12). Patients with recurrent GBM were treated with intravenous administration of siBcl2L12-SNAs (drug moniker: NU-0129), at a dose corresponding to 1/50th of the no-observed-adverse-event level, followed by tumor resection. Safety assessment revealed no grade 4 or 5 treatment-related toxicities. Inductively coupled plasma mass spectrometry, x-ray fluorescence microscopy, and silver staining of resected GBM tissue demonstrated that intravenously administered SNAs reached patient tumors, with gold enrichment observed in the tumor-associated endothelium, macrophages, and tumor cells. NU-0129 uptake into glioma cells correlated with a reduction in tumor-associated Bcl2L12 protein expression, as indicated by comparison of matched primary tumor and NU-0129-treated recurrent tumor. Our results establish SNA nanoconjugates as a potential brain-penetrant precision medicine approach for the systemic treatment of GBM.
引用
- Kumthekar P, Ko CH, Paunesku T, et al. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Sci Transl Med. 2021. PMID: 33692132. doi:10.1126/scitranslmed.abb3945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。